Paper - WANFANG MED ONLINE

You Position: Home > Paper

Evaluation of systemic lupus erythematosus activity: an update

( views:677, downloads:665 )

Author:: No author available

Journal Title:: International Journal of Dermatology and Venereology

Issue:: 4

DOI:: 10.3760/cma.j.issn.1673-4173.2012.04.007

Key Word:: 红斑狼疮,系统性;疾病;活动指数;Lupus erythematosus,systemic;Disease;Activity indices

Abstract： Systemic lupus erythematosus (SLE) is a chronic complex autoimmune disorder with various clinical manifestations and laboratory abnormalities,which have made it difficult to evaluate disease activity.A reliable and sensitive evaluation system can provide essential evidence for the selection of treatment strategies and prediction of prognosis.SLE responder index (SRI),as a new composite measurement system that consists of criteria from 3 different validated indices,including safety of estrogens in lupus erythematosus national assessment-systemic lupus erythematosus disease activity index (SELENA-SLEDAI),physician global assessment (PGA) and the British Isles Lupus Assessment Group (BILAG) 2004,can offer a better guide to the treatment and prediction of prognosis of SLE,so as to facilitate the maintenance of psychosomatic health and improvement of quality of life in patients with SLE.

Reference

[1]陈勇,陈志伟,张哲,等.系统性红斑狼疮患者血清可溶性标准型CD44检测及其临床意义[J].2005,(12).
[2]胡建利,叶冬青,张国庆,等.系统性红斑狼疮疾病活动性指数（SLEDAI）评价指标间内在关系的探讨[J].2006,(3).
[3]Cresswell L,Yee CS,Farewell.Numerical scoring for the Classic BILAG index.[J].2009,48(12).
[4]Gurudu SR,Leighton JA.Assessment and validation of the new capsule endoscopy Crohn's disease activity index (CECDAI): what difference does it make?[J].2009,15(10).
[5]Richard A, Furie,Michelle A, Petri,Daniel J, Wallace,etc.Novel evidence-based systemic lupus erythematosus responder index.[J].2009,61(9).
[6]Tekstra,J.,Bijlsma,J.W.J.,Luijten,K.M.A.C.,etc.The Systemic Lupus Erythematosus Responder Index (SRI); A new SLE disease activity assessment[J].2012,11(5).
[7]Abdulahad DA,Limburg PC,Westra J,etc.High mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their relation to disease characteristics in systemic lupus erythematosus.[J].2011,13(3).
[8]Andrea, Doria,Maurizio, Cutolo,Anna, Ghirardello,etc.Steroid hormones and disease activity during pregnancy in systemic lupus erythematosus.[J].2002,47(2).
[9]Prabu A,Teh LS,Khamashta MA,etc.BILAG-2004 index captures systemic lupus erythematosus disease activity better than SLEDAI-2000.[J].2008,67(6).
[10]Maria Gorette, dos Reis,Izaias Pereira, da Costa.Health-related quality of life in patients with systemic lupus erythematosus in Midwest Brazil.[J].1900,50(4).
[11]Gordon C,Wallace DJ,Shinada S,etc.Testosterone patches in the management of patients with mild/moderate systemic lupus erythematosus.[J].2008,47(3).
[12]Navarra SV,Guzman RM,Gallacher AE,etc.Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.[J].2011,377(9767).
[13]Kiran Farheen,Sandeep K. Agarwal.Assessment of Disease Activity and Treatment Outcomes in Rheumatoid Arthritis[J].2011,17(S.9).
[14]Abrahamowicz M,Ferland D,Chang E,etc.Comparison of the responsiveness of lupus disease activity measures to changes in systemic lupus erythematosus activity relevant to patients and physicians.[J].2002,55(5).
[15]Jimenez-Hernandez M,Escarcega RO,Lopez-Colombo A,etc.Use of rituximab in patients with systemic lupus erythematosus: an update.[J].2009,8(4).
[16]Koh ET,Lau TC,Cheng YK,etc.Enhanced expression of interferon-inducible protein-10 correlates with disease activity and clinical manifestations in systemic lupus erythematosus.[J].2009,156(1).
[17]Buyon J,Gordon C,Hsieh HJ,etc.Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER).[J].2011,20(7).
[18]Friedman A,Buyon JP,Lockshin M,etc.Combined oral contraceptives in women with systemic lupus erythematosus.[J].2005,353(24).
[19]Kristin M, Houghton,Lori B, Tucker,James E, Potts,etc.Fitness, fatigue, disease activity, and quality of life in pediatric lupus.[J].2008,59(4).
[20]Hsieh,H.-J.,Wallace,D.J.,Oates,J.C.,etc.Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial[J].2010,62(1).
[21]Fireman,Z.,Odonnel,S.,Eliakim,R.,etc.Validation of the Capsule Endoscopy Crohns Disease Activity Index (CECDAI or Niv score): A multicenter prospective study[J].2012,44(1).
[22]Hermine I, Brunner,Earl D, Silverman,Claire, Bombardier,etc.European Consensus Lupus Activity Measurement is sensitive to change in disease activity in childhood-onset systemic lupus erythematosus.[J].2003,49.
[23]Yee CS,McElhone K,Teh LS,etc.Assessment of disease activity and quality of life in systemic lupus erythematosus - New aspects.[J].2009,23(4).
[24]Ibanez D,Urowitz MB,Gladman DD.Systemic lupus erythematosus disease activity index 2000.[J].2002,29(2).
[25]Gordon C,Griffiths B,Mosca M.Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices.[J].2005,19(5).
[26]Daca A,Czuszynska Z,Smolenska Z,etc.Two systemic lupus erythematosus (SLE) global disease activity indexes--the SLE Disease Activity Index and the Systemic Lupus Activity Measure--demonstrate different correlations with activation of peripheral blood CD4+ T cells.[J].2011,72(12).